CME Group (CME)
NASDAQFinancialsFinancial Data & Stock ExchangesSnapshot 2026-07-07
$240.75+2.55%
Close 2026-07-07 · 1-day change
Reading CME? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CME free→NASDAQFinancialsFinancial Data & Stock ExchangesSnapshot 2026-07-07
Reading CME? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CME free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
CME represents a durable compounder with a focus on achieving record revenue and earnings. The current thesis state is intact, supported by consistent management priorities and recent financial performance.
The market currently prices CME at a premium compared to peers, reflecting a justified valuation despite recent changes from 'expensive' to 'fair'. There is a low expectations gap, indicating that the market does not assume significant growth beyond current performance.
Management is on track to achieve its goals of record revenue and strong operating income. However, there is a moderate risk due to a history of earnings misses, which could impact future performance.
Key scenarios include potential guidance cuts from management, which could negatively affect sentiment. Additionally, the performance of sector leaders like SPGI, MCO, and ICE will be crucial in determining CME's trajectory.
CME's fundamentals and management execution are solid, but external factors could create volatility. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company is expanding its product offerings and market access. This includes launching new futures and enhancing its cryptocurrency offerings. There are no current threats to the thesis.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show if revenue and earnings growth trends continue. Investors will look for signs of sustained performance.
Confirms:Q2 2026 revenue exceeds $1.9 billion, maintaining the growth trend from Q1.
Disproves:Q2 2026 revenue is below $1.7 billion. This may mean a slowdown.
Why it matters: An update on EPS guidance will show how management views future earnings potential.
Confirms:Management raises EPS guidance for Q2 2026 to above $3.18.
Disproves:Management cuts EPS guidance for Q2 2026. It is now below current expectations.
Why it matters: Updates on capital use will show how CME grows and pays back shareholders.
Confirms one read:CME announces more share buybacks or new capital plans.
Confirms the other:CME halts share repurchase program or cuts dividend payments.
Why it matters: Changes to the dividend could change how investors feel and how they get money back.
Confirms one read:CME Group will have a variable dividend that matches the regular dividend in March 2026.
Confirms the other:CME Group changes or delays the dividend structure. This creates uncertainty for investors.
Why it matters: Average daily volume growth is key to revenue. A decline could signal weakening demand for CME's products.
Confirms:Q2 average daily volume is over 36.2 million contracts. This shows a rising trend.
Disproves:Q2 average daily volume is below 32 million contracts. This may mean less trading.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.